DSIP (Delta Sleep-Inducing Peptide)

Mechanism of action

DSIP (Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a 9-amino-acid endogenous peptide first isolated by Marcel Monnier and colleagues at the University of Basel in the 1970s from cerebral venous blood of rabbits during electrical stimulation of the thalamus, which induced delta-wave EEG activity characteristic of deep slow-wave sleep. The peptide's discovery context — passive transfer of the sleep-inducing factor from stimulated to naive animals — established DSIP as a candidate endogenous sleep regulator, though subsequent research has proven the pharmacology substantially broader than the name suggests. The molecular mechanism of DSIP remains incompletely characterised despite 45+ years of research. Multiple candidate mechanisms have been proposed and partially supported: modulation of GABAergic neurotransmission through indirect effects on GABA-A receptor function; interaction with opioid receptors and modulation of endogenous opioid system tone; modulation of stress-response hormones including CRH and ACTH; direct neuronal calcium channel modulation; and neuroprotective effects through mechanisms that include but are not limited to antioxidant activity. The absence of a clearly defined primary receptor target places DSIP in the pharmacological category of endogenous peptides whose mechanisms are integrated rather than single-target — similar in this respect to Selank, cerebrolysin, and several other research peptides where multiple pathways converge on the observed behavioural and functional endpoints. Sleep-related effects, when observed, include modest reductions in sleep-onset latency, modest increases in slow-wave sleep duration, and normalisation of sleep architecture disturbances in some contexts. The effect magnitude is modest and inconsistent across studies — DSIP is not a hypnotic in the sense of benzodiazepines or z-drugs (zolpidem, zopiclone) but rather a mild sleep-quality modulator with additional pleiotropic effects. Stress-adaptation effects have been more consistently characterised: DSIP administration reduces stress-hormone responses (cortisol, ACTH) to standardised stressor exposure in pre-clinical models and appears to accelerate physiological adaptation to chronic stress paradigms. Neuroprotective effects have been documented in rodent models of ischaemia and toxin exposure, though effect sizes are modest and mechanism attribution complex. The pleiotropic pharmacology has motivated research applications spanning sleep disorders, chronic stress and adaptation research, alcohol and opioid withdrawal (Russian clinical exploration has been particularly notable in this space), and neuroprotection in cerebrovascular and neurodegenerative contexts. None of these applications has translated to registered marketing authorisation in any jurisdiction.

DSIP was discovered through the passive transfer experiments of Marcel Monnier in 1977 — cerebral venous blood from rabbits during sleep-associated delta-wave EEG activity induced sleep when transferred to naive animals. The 9-amino-acid peptide isolated from this activity established the concept of endogenous sleep-modulating peptides, though the subsequent 45+ years of research have proven the pharmacology substantially broader than the sleep-inducing name suggests.

— Notable finding

Research history

DSIP was discovered by Marcel Monnier and colleagues at the University of Basel in 1977 through experiments in which cerebral venous blood collected from rabbits during sleep-associated delta-wave EEG activity produced sleep induction when transferred to naive animals. Bioassay-guided purification of the transferred activity led to isolation of the 9-amino-acid peptide, subsequently named for its sleep-inducing activity. The initial characterisation immediately positioned DSIP as one of the first identified endogenous sleep-regulatory peptides and generated widespread academic interest in the possibility that sleep might be pharmacologically controlled by a small number of specific endogenous factors. Academic characterisation across the 1980s and 1990s explored the pharmacology across sleep, stress, opioid-modulation, and neuroprotection contexts. Russian and Eastern European clinical exploration explored DSIP in alcohol and opioid withdrawal, chronic stress conditions, and various psychiatric contexts — this Russian clinical research produced a substantial regional literature but did not translate to Western regulatory framework marketing authorisation. Several small Western academic groups continued mechanistic pharmacology work through the 2000s, though funding for endogenous-peptide sleep research declined as the sleep-medicine field shifted toward receptor-defined orexin and melatonin approaches. Western pharmaceutical development has not been pursued in earnest. The combination of the incompletely characterised mechanism, the modest and inconsistent effect sizes, and the absence of a clear regulatory pathway for a pleiotropic endogenous peptide has prevented commercial development. DSIP has remained an academic-research and research-chemical compound rather than a clinical-development target. A small number of academic groups continue to publish characterisation work as recently as the mid-2020s. In the research-chemical-community context, DSIP has moderate visibility as a sleep-and-stress research peptide alongside Selank and other stress-adaptation compounds. Research-chemical supply is widely available at moderate cost, though grey-market suppliers routinely overstate the sleep-quality effect sizes documented in the primary literature. As of 2026, DSIP holds no marketing authorisation in any jurisdiction. No active commercial development programme is known.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

DSIP has a favourable pre-clinical and limited-clinical safety profile accumulated through Russian clinical exploration and Western pre-clinical work. The adverse-event profile is minimal: injection-site reactions are the most common; occasional mild headache or fatigue reported. No clinically significant changes in routine haematology, biochemistry, or vital signs have been documented at therapeutic doses. As an endogenous peptide, immunogenicity risk is low. The rapid peptidase-mediated clearance also limits systemic exposure duration, further reducing the likelihood of cumulative or chronic-exposure adverse phenomena. The multi-pathway pharmacology could theoretically produce broader effects with chronic dosing than the acute-dosing safety data document, but chronic-dosing safety pharmacology is incompletely characterised beyond the Russian clinical experience. Theoretical safety considerations centre on the incompletely characterised receptor pharmacology. Chronic modulation of GABAergic, opioid, and stress-hormone systems could theoretically produce dependence-like phenomena or tolerance, though these have not been consistently documented in Russian clinical experience or Western pre-clinical work. Concurrent administration with clinically-established hypnotics (benzodiazepines, z-drugs), opioids, or CNS depressants is theoretically concerning on mechanistic grounds and has not been characterised in controlled studies. Practitioners of research-chemical-community DSIP use commonly stack the compound with melatonin, valerian, or over-the-counter sleep aids; the pharmacological interactions of these combinations are not documented. Pregnancy and lactation are not characterised — the endogenous role of DSIP in developing organisms and in reproductive physiology has not been sufficiently studied to support use in these populations, and the compound should be avoided. No serious adverse events have been reported in any published DSIP research. The acute safety profile is favourable; chronic-dosing safety pharmacology is incompletely characterised beyond the Russian clinical experience.

UK regulatory status

DSIP is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within any specific UK controlled-substance framework. Research-grade material is available from research-chemical suppliers for legitimate laboratory research; possession for bona fide research is generally unrestricted in the UK. Supply or administration of DSIP to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence — supplying, offering to supply, or advertising for supply of an unauthorised medicine to a member of the public are the specific offences that most commonly arise. Advertising and marketing DSIP for sleep, stress, or any therapeutic claim to UK consumers engages Advertising Standards Authority (ASA) enforcement in addition to MHRA jurisdiction over unlicensed-medicine promotion. Cosmetic-industry positioning has not been attempted for DSIP. DSIP is not currently on the WADA Prohibited List. Its sleep and stress-modulation mechanisms do not fall within any current WADA category. Athletes should nevertheless note that unlicensed peptides carry inherent contamination-risk under the strict-liability anti-doping framework. For animal research under the Animals (Scientific Procedures) Act 1986 (ASPA), DSIP work in vertebrates requires standard project and personal licences.

Frequently asked questions